News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
3h
Zacks.com on MSNFDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger AdultsArexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.
8h
GlobalData on MSNGSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patientsThe label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results